Fig. 1.

Sirtinol prolongs the cardiac allograft survival in murine cervical heterotopic cardiac transplant model. a Fully MHC-mismatched cardiac allograft recipients (BALB/C to C57BL/6) were treated with DMSO, sirtinol (1 mg/kg/day) by intraperitoneal injection since the day receiving transplantation until when cardiac arrest occurred. Graft survival was assessed every day. b Pathological examination of allografts harvested on day 7 post-transplantation. Shown are section graphs from the low power field and high power field. c Infiltrating cells per high field were counted from five mice per group. *P < 0.05, **P < 0.01, compared with DMSO group